NervGen Pharma to Delist From TSX Venture Exchange
MT Newswires Live
Mar 13
NervGen Pharma (NGEN) said late Thursday it elected to voluntarily delist its common shares from the TSX Venture Exchange, effective at the close of markets Monday.
The move is intended to eliminate duplicative exchange fees, reduce legal, accounting and regulatory complexity, and allow greater focus on clinical execution and long-term shareholder value.
NervGen said all shareholders, including those in Canada, will continue to have full trading access to their common shares on Nasdaq.
In connection with the voluntary delisting, the company said it has terminated its at-the-market equity program launched on Dec. 19, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.